If you are between the ages of 18 and 65 and have moderate to severe nasal polyps, then you may be eligible to participate in a clinical research trial at Brigham and Women’s Hospital. The study drug, called AK001, is believed to reduce two types of inflammatory white blood cells in nasal polyp tissue. This drug has not yet been approved by the Federal Drug Administration.

The study requires nine in-clinic visits over a period of about six months, during which time you will receive the study drug through three separate IV infusions. Visits will include a physical examination, blood and urine collections, a series of written questionnaires, a lung function test, an evaluation of sense of smell, and a nasal endoscopy. A sinus CT scan will also be performed at the beginning and end of the study. You will be treated by a medical doctor and receive the study medication at no cost to you.

The purpose of this research study is to find out if AK001 will improve symptoms associated with moderate to severe nasal polyps. You will be compensated $100 for each completed visit. For more information, please contact Marina Palumbo at mpaulmbo3@partners.org or Dr. Tanya Laidlaw at tlaidlaw@partners.org